EAPH (Easton Pharmaceuticals) EBIT: $-0.26 Mil (TTM As of Sep. 2021)


EAPH Easton Pharmaceuticals Inc EAPH
12 GF Score
Price $0.00
View Full Analysis

What is Easton Pharmaceuticals EBIT?

Easton Pharmaceuticals EAPH -95.00% 12 EBIT is $-0.26 Mil as of Sep. 2021. GuruFocus rates EAPH with a GF Score™ of 12/100.

Easton Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2021 was $-0.08 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2021 was $-0.26 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Easton Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2021 was -3.38%. Easton Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2021 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Easton Pharmaceuticals  (OTCPK:EAPH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Easton Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2021 is calculated as:

ROC % (Q: Sep. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2021 ) + Invested Capital (Q: Sep. 2021 ))/ count )
=-0.336 * ( 1 - 0% )/( (9.898 + 9.968)/ 2 )
=-0.336/9.933
=-3.38 %

where

Invested Capital(Q: Jun. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9.898 - 0.157 - ( 0 - max(0, 0.157 - 0+0))
=9.898

Invested Capital(Q: Sep. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9.968 - 0.233 - ( 0 - max(0, 0.233 - 0+0))
=9.968

Note: The Operating Income data used here is four times the quarterly (Sep. 2021) data.

2. Joel Greenblatt's definition of Return on Capital:

Easton Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2021 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2021 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2021  Q: Sep. 2021
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.336/( ( (0 + max(-0.157, 0)) + (0 + max(-0.233, 0)) )/ 2 )
=-0.336/( ( 0 + 0 )/ 2 )
=-0.336/0
= %

where Working Capital is:

Working Capital(Q: Jun. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0.157 + 0 + 0)
=-0.157

Working Capital(Q: Sep. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0.233 + 0 + 0)
=-0.233

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2021) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Easton Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2021 )
=-0.261/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Easton Pharmaceuticals EBIT Related Terms

Easton Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for Easton Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Easton Pharmaceuticals EBIT Chart

Easton Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec18 Dec19 Dec20
EBIT
Get a 7-Day Free Trial -1.84 -3.41 -0.12 -0.32 -0.19

Easton Pharmaceuticals Quarterly Data
Jun02 Sep02 Dec02 Mar03 Jun03 Sep03 Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec18 Dec19 Dec20 Mar21 Jun21 Sep21
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.10 -0.08 -0.08

EAPH vs FPSUF, GCAN, ACUR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Easton Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Easton Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Easton Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Easton Pharmaceuticals's EV-to-EBIT falls into.


EAPH
12GF Score
Easton Pharmaceuticals Inc EAPH
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Easton Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-0.26 Mil mean?
Easton Pharmaceuticals (EAPH) has a EBIT of $-0.26 Mil as of Sep. 2021. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Easton Pharmaceuticals.
Is Easton Pharmaceuticals' EBIT too high?
Easton Pharmaceuticals' current EBIT is $-0.26 Mil. Overall, Easton Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Easton Pharmaceuticals' EBIT compare to FPSUF and GCAN?
Easton Pharmaceuticals' EBIT of $-0.26 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Easton Pharmaceuticals. Easton Pharmaceuticals's current EBIT is $-0.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Easton Pharmaceuticals stock overvalued right now?
Easton Pharmaceuticals (EAPH) has a current EBIT of $-0.26 Mil. The current EBIT is $-0.26 Mil. Easton Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Easton Pharmaceuticals (EAPH), the current EBIT is $-0.26 Mil as of Sep. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Easton Pharmaceuticals Business Description

Address 2 Bloor Street East, Suite 3500, Toronto, ON, CAN, M4W 1A8
Easton Pharmaceuticals Inc is a diversified specialty pharmaceutical company. It owns and develops proprietary transdermal delivery technology and therapeutic over the counter products and drugs to treat cancer and other diseases. The company also owns exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products. It is focused on the development of product Viorra. The firm's products include Nauseasol, Skin Renou HA, Kenestrin gel, and XILIVE, among others.
12GF Score

Get the complete analysis for EAPH

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price